◆ TICKERBASEVisão interativa →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

InícioTodas as ações › PCVX · English version

Vaxcyte Inc (PCVX)

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

HEALTHCARE · Wall Street (EUA) · Última atualização: 2026-08-11

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Números-chave

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultadosTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Receita total$0M$0M$0M$0M$0M$0M$0M$0M$0M
Lucro bruto($16M)($75M)($9M)($2M)($1M)($1M)($1M)
Margem Bruta %
Resultado Operacional (EBIT)($1.2B)($924M)($570M)($468M)($232M)($104M)($90M)($54M)($36M)($18M)
% de margem operacional
Resultado líquido($1.1B)($767M)($464M)($402M)($223M)($100M)($89M)($50M)($29M)($17M)
Margem Líquida %
EBITDA($1.1B)($742M)($448M)($392M)($214M)($97M)($88M)($49M)($28M)($17M)
Lucro por ação (EPS)$-7.64$-5.63$-3.80$-4.14$-3.44$-1.93$-3.02$-1.03$-1.15$-4.83
Ações em circulação (M)144M136M122M97M65M52M30M49M4M

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de PCVX. /companies/us/PCVX

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.